CFA
MRNA icon

Carroll Financial Associates’s Moderna MRNA Stock Holding History

Carroll Financial Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$61K Sell
248
-1
-0.4% -$292 ﹤0.01% 664
2021
Q3 		$95K Sell
249
-175
-41% -$64.5K 0.01% 549
2021
Q2 		$99K Buy
424
+23
+6% +$4.11K 0.01% 587
2021
Q1 		$52K Hold
401
– – ﹤0.01% 759
2020
Q4 		$41K Buy
401
+35
+10% +$3.54K ﹤0.01% 751
2020
Q3 		$25K Buy
366
+60
+20% +$4.18K ﹤0.01% 805
2020
Q2 		$19K Sell
306
-30
-9% -$1.64K ﹤0.01% 866
2020
Q1 		$10K Buy
+336
New +$7.73K ﹤0.01% 944

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Carroll Financial Associates's MRNA Position: Q4 2021 in Review

Carroll Financial Associates reduced its Moderna (MRNA) stake by 0.4% in Q4 2021, selling an estimated $292 and leaving 248 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #664.

Carroll Financial Associates first reported a position in MRNA in Q1 2020 and has held it in 8 quarters since. The position peaked at $99K in Q2 2021. 1,110 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

  • Carroll Financial Associates held 248 shares of Moderna worth $61K as of Q4 2021.
  • Carroll Financial Associates sold 1 Moderna share in Q4 2021, an estimated $292.
  • Moderna made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #664 holding.
  • Carroll Financial Associates first reported a position in Moderna in Q1 2020 and has held it in 8 quarters since.
  • Carroll Financial Associates's Moderna position peaked at $99K in Q2 2021.
  • 1,110 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.